chen, chenyan – page 11 – eisai china lnc.-pg电子app

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that eisai presented new data from study 202, a phase ii evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of irregular sleep-wake rhythm disorder (iswrd) in patients with mild to moderate alzheimer’s disease. the data were presented at the 11th clinical trials in alzheimer’s disease (ctad) conference in barcelona, spain. lemborexant is being developed for the treatment of multiple sleep-wake disorders, including insomnia disorder.

on october 23, 2018, eisai china inc. was invited to attend the “health to countryside” activity held in duyun city, qiannan autonomous prefecture, guizhou province by the national committee for education, science, culture, health and sports of chinese people’s political consultative conference (cppcc), and donated medicines worth rmb510,000 yuan to the local health commission. eisai china acts in accordance with the corporate philosophy of human health care (hhc) and practices social responsibilities all along, donating medicines worth rmb450,000, rmb490,000, rmb500,000, rmb540,000 and rmb510,000 respectively to this project from the year 2014 to 2018, with the total worth of medicines reaching up to approximately rmb2.5 million yuan.

tokyo and stamford, conn. – october 17, 2018 – eisai co., ltd. (ceo: haruo naito, “eisai”) and purdue pharma l.p. (president and ceo: craig landau, “purdue pharma”) today announced positive topline results from sunrise 2, a long-term phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. topline results reported today are the primary and key secondary outcomes of the study from the six-month, placebo-controlled treatment period; the study is ongoing to 12 months. eisai and purdue pharma plan to present full results from sunrise 2 at upcoming medical meetings in 2019.

tokyo and kenilworth, n.j. sept. 5, 2018 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth n.j., u.s.a., known as msd outside of the united states and canada, announced today that the china national medical products administration (nmpa) approved the kinase inhibitor lenvima® (lenvatinib) as a single agent for the treatment of patients with unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy. in china, the application of lenvima was submitted in october 2017, and was designated for priority review by the nmpa due to lenvima’s significant clinical benefit compared to existing treatments, leading to approval in approximately 10 months. this approval marks the first for lenvima in china, where the incidence of hcc is high,1 and the first new systemic therapy approved for the first-line treatment of unresectable hcc in china in ten years.1

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) has announced that results from the cardiovascular outcomes trial (camellia-timi 61) in patients treated with lorcaserin hydrochloride (generic name, product name in the u.s.: belviq®, “belviq”) were highlighted in an oral presentation at the european society of cardiology (esc) congress 2018 held in munich, germany, and concurrently published in the new england journal of medicine, one of the world’s most influential medical journals.1 belviq is the first ever weight loss medication approved for chronic weight management which has been proven to not increase the incidence of major cardiovascular (cv) events in a dedicated long-term cardiovascular outcome trial.